Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs sevoflurane for one-lung ventilation in infants and young children
ChiCTR2600124670Phase 4Not yet recruiting
- Sponsor
- Bozhou People's Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam in Congenital cystic adenomatoid malformation of lung (CPAM) (2 arms), sponsored by Bozhou People's Hospital. Primary endpoint: P/F ratio. Planned start May 2026; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
Congenital cystic adenomatoid malformation of lung (CPAM)
Beyond the preview
Go deeper on ChiCTR2600124670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124670.